Compare Salesforce Inc (CRM) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Incyte Corporation — how do they compare? Salesforce Inc trades at $167.47 (market cap $137.23B), while Incyte Corporation trades at $115.26 (market cap $22.95B). The key difference: Salesforce Inc is far larger — about 6× Incyte Corporation's market cap, and Salesforce Inc pays a 1.05% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| CRM | INCY | |
|---|---|---|
Market Cap | $137.23B | $22.95B |
Sector | Technology | Health |
52-Week High | $270.25 | $118.52 |
52-Week Low | $150.12 | $67.38 |
Enterprise Value | $167.28B | $18.97B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $167.70, down 2.06% amid broader software sector weakness. The stock shows strong fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs $3.13 expected) and robust profitability (77.6% gross margin). Technical indicators are neutral with support at $165 and resistance at $171. Recent AI-driven growth initiatives, including Agentforce reaching $2.9B ARR, position the company for continued expansion despite current market pressures.
CRM presents a compelling long-term opportunity with 76.8% analyst buy ratings and a $235.90 consensus target (40% upside). Risks include sector volatility from AI competition and macroeconomic headwinds, but strong cash flow generation ($13.1B operating cash flow in 2025) and market leadership support the bullish case for patient investors.
Incyte (INCY) trades at $114.23, down 2.12% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.81, and revenue growth continues with 2025 revenue at $5.14 billion. Recent developments include positive Phase 1/2 data for VGA039 and the acquisition of Vega Therapeutics, expanding its hematology portfolio.
Outlook remains positive with analyst consensus favoring a Buy rating and a $112.78 price target. Key opportunities include pipeline advancements and robust profitability margins, while risks involve regulatory hurdles and competitive pressures in the biopharmaceutical sector. Earnings growth and product approvals are critical catalysts for future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
